UK launches whole-genome sequencing pilot for babies - Nature Biotechnology

In Brief: The UK launches a program to test whether whole-genome sequencing can speed up the diagnosis and access to treatment for babies born with genetic diseases

Currently in the UK, heel prick tests screen for nine specific conditions in newborns. The new program, the largest of its kind in the world, will sequence the genomes of 100,000 newborn babies. The aim is to define whether whole-genome sequencing can detect 200 disorders that affect 3,000 babies born each year in the UK.

The focus will be on conditions where interventions exist that could reduce disability or potentially avoid harm; for example, dietary shifts or vitamin supplements, says Mark Caulfield, vice-principal for health for the Faculty of Medicine and Dentistry at Queen Mary University of London, who leads the program. The program will be voluntary and run alongside the heel prick test.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NatureBiotech /  🏆 231. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Chem-map profiles drug binding to chromatin in cells - Nature BiotechnologyHow small molecules bind chromatin and DNA is determined by Chem-map.
Read more »

Precise transcript targeting by CRISPR-Csm complexes - Nature BiotechnologyThe bacterial Csm complex efficiently knocks down eukaryotic nuclear and cytoplasmic RNAs.
Read more »

Hiking With Your Dog Off-Leash Could Create Problems for NatureConservationists say an off-leash pet dog can cause unexpected harm in natural spaces, including habitat disturbance and wildlife stress or attacks.
Read more »

Cardano Network Quickly Recovers After Brief Node OutageThe Cardano network saw a brief outrage that was automatically fixed within minutes on Sunday. By shauryamalwa.
Read more »

Off-the-shelf CAR T cells for multiple myeloma - Nature MedicineNews & Views: Jennifer Brudno & James Kochenderfer theNCI discuss off-the-shelf CARTcells. A phase 1 trial in melanoma shows feasibility and preliminary efficacy, but how might these fit into the treatment landscape?
Read more »